- Full year 2022 total revenue expected to be approximately
$44.3 million, representing growth of
31% over full year 2021
- Fourth quarter 2022 total revenue expected to be
approximately $12.4 million,
representing growth of 22% over fourth quarter 2021
- Installed base at year end 2022 of greater than 600
instruments compared to over 500 instruments at year end
2021
- Total SPL partnerships of 18 at year end 2022, including 3
added in 2022; additional SPL partnership with Catamaran Bio signed
in January 2023
- Initial 2023 guidance for total revenue growth 21% to 26%
over 2022, including core revenue growth of 20% to 25% over 2022,
and SPL program-related revenue of approximately $6 million
ROCKVILLE, Md. ,
March 6,
2023 /PRNewswire/ -- MaxCyte, Inc., (NASDAQ: MXCT)
(LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative cell-based research, today
announced preliminary revenue results for the fourth quarter and
full year 2022 and provided initial 2023 revenue guidance.
Preliminary Unaudited Fourth Quarter and Full Year 2022
Revenue
Management expects total revenue for the fourth quarter of 2022
to be approximately $12.4 million, up
from $10.2 million in the fourth
quarter of 2021, reflecting growth of approximately 22% including
approximately 4% growth in core business revenue. Revenue for the
quarter ended December 31, 2022
includes approximately $1.9 million
of Strategic Platform Licenses ("SPLs") program-related revenue,
compared to immaterial program-related revenue in the fourth
quarter of 2021.
Total revenue for the year ended December
31, 2022 is expected to be approximately $44.3 million, up from $33.9 million in full year 2021, reflecting
growth of approximately 31% in total revenue and approximately 26%
in core business revenue. Revenue for the year ended December 31, 2022 includes approximately
$4.6 million of SPL program-related
revenue, compared to $2.5 million of
program-related revenue in 2021.
MaxCyte's revenue is derived from its core business (sales and
leases of instruments and sales of disposables to cell therapy and
drug discovery customers), as well as program-related revenue from
SPL agreements.
MaxCyte ended the year with 18 SPL partnerships, including 3 SPL
partnerships added during 2022 with Intima Bioscience, LG Chem, and
Curamys. MaxCyte signed an SPL partnership agreement with Catamaran
Bio in January 2023, bringing the
current total number of SPL partnerships to 19.
"We delivered strong growth across the business in 2022, giving
us confidence as reflected in our initial 2023 revenue guidance,"
said Doug Doerfler, President and
CEO of MaxCyte. "Our diverse and robust partnership portfolio
continues to grow with three new partnerships added in 2022, in
addition to the signing of a partnership with Vertex
Pharmaceuticals following the transfer from CRISPR Therapeutics for
the development of its CRISPR/Cas9-based gene-edited therapy
(exa-cel, formerly known as CTX001™). We were pleased to announce
an additional partnership in January
2023 with Catamaran Bio to support their CAR-NK cell therapy
programs for solid tumors. We look forward to further expansion of
our partnerships based on a strong pipeline and the continued
progression of our partners' programs as they move into and through
the clinic towards commercialization."
In addition to revenue, management regularly reviews key
business metrics to evaluate MaxCyte's business, measure
performance, identify trends affecting its business, formulate
financial projections and make strategic decisions. As of the dates
presented, these key metrics were as follows:
|
|
As of
December 31,
|
|
|
2022
|
2021
|
2020*
|
Installed base of
instruments (sold or leased)
|
|
>600
|
>500
|
>400
|
Number of active SPL
partnerships
|
|
18
|
15
|
12
|
Total number of
licensed clinical programs (SPL partnerships only)
|
|
>125
|
>95
|
>75
|
Total number of active
licensed clinical programs under SPL partnerships currently in the
clinic**
|
|
16
|
15
|
7
|
Total potential
pre-commercial milestones under SPL partnerships
|
|
>$1.55
billion
|
>$1.25
billion
|
>$950
million
|
* Amounts presented as of December 31,
2020, give effect to one SPL entered into and additional
INDs cleared in January 2021.
** Number of licensed clinical programs under SPLs are by number
of product candidates and not by indication.
MaxCyte's fourth quarter and full year 2022 financial results
presented in this release are preliminary and unaudited and are
subject to revision based on the completion of MaxCyte's normal
quarter and year-end process and year-end audit. As a result, these
preliminary results may differ from the audited actual results that
will be reflected in MaxCyte's consolidated financial statements
for the year ended December 31, 2022,
which we expect to issue on March 15,
2023.
2023 Revenue Guidance
Management is providing initial 2023 revenue guidance for total
revenue, core business revenue and SPL program-related revenue.
Management expects full year 2023 total revenue growth between
21% and 26% over 2022, including core business revenue growth
between 20% and 25% over 2022, and SPL program-related revenue of
approximately $6 million.
Fourth Quarter and Full Year Financial Results
MaxCyte will report full 2022 financial results and host a
conference call on March 15, 2023, at
4:30 p.m. Eastern Time. Investors
interested in listening to the conference call are required to
register online. A live and archived webcast of the event will be
available on the "Events" section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™ GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including but not limited
to, statements regarding our expected revenue for the quarter and
year ended December 31, 2022,
expected total revenue growth, core business revenue growth and SPL
program-related revenue for the year ending December 31, 2023, expansion of and revenue
from our SPLs and the progression of our customers' programs into
and through clinical trials. The words "may," "might," "will,"
"could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "expect," "estimate," "seek," "predict,"
"future," "project," "potential," "continue," "target" and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with the timing of our customers'
ongoing and planned clinical trials; the adequacy of our cash
resources and availability of financing on commercially reasonable
terms; general market and economic conditions that may impact
investor confidence in the biopharmaceutical industry and affect
the amount of capital such investors provide to our current and
potential partners; and demand for our products. These and other
risks and uncertainties are described in greater detail in the
section entitled "Risk Factors" in our Annual Report on Form 10-K
for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 22, 2022, as well as discussions of
potential risks, uncertainties, and other important factors in the
other filings that we make with the Securities and Exchange
Commission from time to time. These documents are available under
the "SEC filings" page of the Investors section of our website at
http://investors.maxcyte.com. Any forward-looking statements
represent our views only as of the date of this press release and
should not be relied upon as representing our views as of any
subsequent date. We explicitly disclaim any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
MaxCyte Contacts:
US IR Adviser
Gilmartin
Group
David Deuchler,
CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Seismic Collaborative, A Spectrum Science
Company
Valerie Enes
+1 408-497-8568
valerie@teamseismic.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma
Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
View original
content:https://www.prnewswire.co.uk/news-releases/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-revenue-results-and-provides-2023-revenue-guidance-301763656.html